By reprogramming TAMs toward an M1 phenotype, these interventions may help overcome immune exclusion, particularly in subtypes like clear cell carcinoma (CCC), where CXCL10-producing macrophages are scarce. Here, CXCL10 is linked to clear cell adenocarcinoma.